Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.

MLA

Fang, Douglas D., et al. “Discovery of a Novel ALK/ROS1/FAK Inhibitor, APG-2449, in Preclinical Non-Small Cell Lung Cancer and Ovarian Cancer Models.” BMC Cancer, vol. 22, no. 1, July 2022, pp. 1–15. EBSCOhost, https://doi.org/10.1186/s12885-022-09799-4.

APA

Fang, D. D., Tao, R., Wang, G., Li, Y., Zhang, K., Xu, C., Zhai, G., Wang, Q., Wang, J., Tang, C., Min, P., Xiong, D., Chen, J., Wang, S., Yang, D., & Zhai, Y. (2022). Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models. BMC Cancer, 22(1), 1–15. https://doi.org/10.1186/s12885-022-09799-4

Chicago

Fang, Douglas D., Ran Tao, Guangfeng Wang, Yuanbao Li, Kaixiang Zhang, Chunhua Xu, Guoqin Zhai, et al. 2022. “Discovery of a Novel ALK/ROS1/FAK Inhibitor, APG-2449, in Preclinical Non-Small Cell Lung Cancer and Ovarian Cancer Models.” BMC Cancer 22 (1): 1–15. doi:10.1186/s12885-022-09799-4.